CombiGene AB AI Stock Analysis
Want to see SE:LARK full AI Analyst Report?
CombiGene AB (LARK) AI Stock Analysis
CombiGene AB
(Nasdaq OMX AB:LARK)
The overall score of 41 reflects severe fundamental and technical challenges. The most critical risks stem from highly questionable valuation metrics, namely an anomalous dividend yield and high P/E ratio, coupled with deep operational unprofitability and ongoing cash burn. Furthermore, persistent bearish price trends across all major moving averages underscore a lack of investor confidence. While the company's zero-debt balance sheet provides a necessary anchor against immediate financial distress, the relentless erosion of equity demands substantial operational turnarounds.
CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 44.75M
- Dividend Yield
- 88.11%
- Average Volume (3M)
- 7,747
- Price to Earnings (P/E)
- 38.5
- Beta (1Y)
- 0.05
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 1
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Asset Management
CombiGene AB Business Overview & Revenue Model
Company Description
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet pr...
CombiGene AB Financial Statement Overview
Summary
Financial performance is heavily weighed down by extreme revenue volatility, persistent cash burn, and negative gross profitability, though a pristine zero-debt balance sheet prevents immediate insolvency.
Income Statement
35NegativeBalance Sheet
70PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 642.00K | 0 | 326.00K | 5.54M | 26.70M | 84.04M |
| Gross Profit | -2.14M | -8.16M | -46.78M | -21.29M | -19.20M | 15.16M |
| EBITDA | 2.72M | -7.19M | -43.15M | -35.98M | -5.86M | 23.56M |
| Net Income | 1.20M | -12.36M | -44.88M | -35.66M | -6.16M | 20.96M |
Balance Sheet | ||||||
| Total Assets | 57.56M | 56.73M | 75.88M | 120.61M | 158.22M | 166.22M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 5.84M | 73.75M | 101.44M | 131.78M | 136.74M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 846.00K | 1.24M | 4.30M | 4.16M | 6.10M | 7.94M |
| Stockholders Equity | 56.71M | 55.49M | 71.58M | 116.46M | 152.12M | 158.28M |
Cash Flow | ||||||
| Free Cash Flow | -2.57M | -12.78M | -29.95M | -30.67M | -16.67M | 21.97M |
| Operating Cash Flow | -2.57M | -12.78M | -29.95M | -30.56M | -16.67M | 22.11M |
| Investing Cash Flow | -49.97M | -49.78M | -81.00K | -988.90K | 0 | -147.73K |
| Financing Cash Flow | 0 | -3.96M | 0 | 0 | 0 | 65.88M |
CombiGene AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.27 is below the 20-day moving average (MA) of 2.31, below the 50-day MA of 2.28, and above the 200-day MA of 2.24, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 58.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.
CombiGene AB Peers Comparison
Overall Rating
SE:EQT59Neutral
SE:LARK41Neutral
SE:ATIN38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| 59Neutral | SEK 382.36B | 31.52 | ― | 1.52% | -18.18% | 20.49% | |
| 41Neutral | SEK 44.75M | 38.47 | 2.14% | 88.11% | ― | ― | |
| 38Underperform | SEK 289.46M | -5.32 | ― | ― | -33.93% | -9.82% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:LARK | CombiGene AB | 2.27 | 0.06 | 2.71% | |
| SE:ATIN | Athanase Innovation AB | 15.00 | 0.00 | 0.00% | |
| SE:EQT | EQT AB | 306.00 | -10.29 | -3.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026
